share_log

C4 Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Siegel Jolie

SEC announcement ·  Mar 8 19:22
Summary by Moomoo AI
Jolie Siegel, the Chief Legal Officer of C4 Therapeutics, Inc. (CCCC.US), has engaged in a transaction involving the company's stock on March 7, 2024. The specific details of the transaction, including the number of shares, nature of the shares, transaction price, and the total value of shares, were not disclosed in the announcement. The action reflects a change in the holdings of a key insider within the company, which may be of interest to investors monitoring insider activities as an indicator of the company's performance and future prospects.
Jolie Siegel, the Chief Legal Officer of C4 Therapeutics, Inc. (CCCC.US), has engaged in a transaction involving the company's stock on March 7, 2024. The specific details of the transaction, including the number of shares, nature of the shares, transaction price, and the total value of shares, were not disclosed in the announcement. The action reflects a change in the holdings of a key insider within the company, which may be of interest to investors monitoring insider activities as an indicator of the company's performance and future prospects.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more